Phillip A. Sharp Sells 11,250 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $278.76 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a market capitalization of $35.95 billion, a PE ratio of -106.40 and a beta of 0.34. The business’s 50-day moving average price is $247.13 and its 200 day moving average price is $260.30. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter in the prior year, the firm posted $1.15 EPS. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Souders Financial Advisors raised its holdings in Alnylam Pharmaceuticals by 1.0% in the second quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after buying an additional 36 shares during the period. Huntington National Bank raised its stake in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the period. SYM FINANCIAL Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 55 shares in the last quarter. Lindbrook Capital LLC boosted its position in Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 57 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its position in Alnylam Pharmaceuticals by 0.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company’s stock worth $1,532,000 after purchasing an additional 58 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on ALNY. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Raymond James lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Piper Sandler reissued an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Finally, Bank of America boosted their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.61.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.